The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer.
about
Adverse events associated with hormonal therapy for prostate cancerMetabolic complications of androgen deprivation therapy for prostate cancerTestosterone for the aging male; current evidence and recommended practiceAndrogen deprivation therapy and cardiovascular disease: what is the linking mechanism?Adverse effects of androgen deprivation therapy in men with prostate cancer: a focus on metabolic and cardiovascular complicationsImpact of Diet-Induced Obesity and Testosterone Deficiency on the Cardiovascular System: A Novel Rodent Model Representative of Males with Testosterone-Deficient Metabolic Syndrome (TDMetS)A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patientsAdvances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapyHormone replacement therapy and physical function in healthy older men. Time to talk hormones?Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer.Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study.Welcoming low testosterone as a cardiovascular risk factorLifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an updateAdverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.Management of complications of prostate cancer treatment.Cardiac and cognitive effects of androgen deprivation therapy: are they real?Contemporary role of androgen deprivation therapy for prostate cancerAndrogen receptor roles in insulin resistance and obesity in males: the linkage of androgen-deprivation therapy to metabolic syndromeEnergetics in colorectal and prostate cancer.Can exercise ameliorate treatment toxicity during the initial phase of testosterone deprivation in prostate cancer patients? Is this more effective than delayed rehabilitation?Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation OncologyAndrogen deprivation therapy for prostate cancer: new concepts and concerns.Gonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome?Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors.Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study.Cardiovascular risk during hormonal treatment in patients with prostate cancer.Estrogenic side effects of androgen deprivation therapy.Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study.Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risksMetabolic effects of androgen deprivation therapyDiabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.Testosterone level in men with type 2 diabetes mellitus and related metabolic effects: A review of current evidence.Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis.Metabolic complications and increased cardiovascular risks as a result of androgen deprivation therapy in men with prostate cancer.Acute testosterone deprivation reduces insulin sensitivity in menCardiometabolic and skeletal risk factors in black men with prostate cancer starting androgen deprivation therapy.Gonadal and Adrenal Abnormalities in Drug Users: Cause or Consequence of Drug Use Behavior and Poor Health OutcomesEfficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer.Sex differences in primary hypertension.Androgen-deprivation therapy and risk for biliary disease in men with prostate cancer
P2860
Q24548201-F6EE1FE5-5613-4E64-A43B-758E3EB2BEABQ24616159-73667B35-C644-4FD5-9AC0-0B027268C35BQ24647679-2B9FAB09-EE07-45A1-9520-0ED1A9CBC6A1Q26749088-F12AEEBA-DC00-40E7-9792-8BF60F00D833Q26852930-8D08446C-7857-46A3-85CF-7B741B6D3604Q27318055-8B658669-213B-4615-8181-E3CC2706CBF0Q28076622-50F576FD-B303-4DEB-8422-4EE864E8D264Q28829239-A96614AB-CD54-4555-919B-24AE84933CCDQ33569163-107CC089-5703-4602-A074-29E08B3E0550Q33594364-493BFE47-8449-4EF0-93FD-90D3DCDDD509Q33677118-B8E6CC77-8E29-4819-81CA-C1CA5580E505Q33710349-D858DFBA-3E9C-4429-A690-08673E6644F5Q33900049-45B0485E-87B9-4718-950B-66CF7E23236AQ33977523-592CCBEC-11F1-458F-87DD-2CE490D36C83Q33978360-D6343ADC-8A19-4714-8395-516830408B67Q34111628-982158BB-80AF-4B04-AB9C-DB7854A93C9EQ34211155-BA937AB3-46C7-4802-A289-0F86F4BD10C1Q34227893-D12D55F1-03F2-444C-B8A6-03D93446E9CDQ34315768-C6656745-4ADA-400A-8991-0BFEF5141A6FQ34421944-DC263A94-D3DB-4324-9CD6-F05A842003C0Q34505196-B3D8208E-74BC-45FE-9FAB-F7C1B75D12F4Q34617845-0ABA71C3-BFBD-405C-9B7A-98AF041E39FDQ34617897-54C313BC-BDF8-48D0-BCE9-022B6A5A5809Q34617924-F072A5E5-8E72-4DA1-A241-B49EE186CF00Q34629714-EDC4FAF9-4E4D-44C8-8B04-7ECE72B0F082Q34721165-84C8BABC-34E2-4A44-864E-EE2D553833D0Q34743239-2075AA64-B6DC-45B6-8370-F6FD88D4192EQ34804834-249C9160-2165-4D9D-96A3-21C79D684526Q34960686-71A730AA-0A76-47C1-8208-7C62C07CA9F2Q34962416-73196D1A-223D-4BC9-8A5A-24B2412EA210Q35022837-8D0B2E32-BEA9-4022-8827-C64473946B66Q35192163-35BF0631-25EC-43B0-B6D0-FA0D24A2C59BQ35202889-16F0875D-F0D6-4659-A482-5D0C9036A796Q35433102-12C28E60-3839-4627-90DD-398899BC30E1Q35573457-D96D562C-850C-4243-B2CB-9F376799176DQ35614699-BC955A42-1B05-48B8-9482-09DF81D24C8CQ35678022-16B615C0-7AE6-4DFD-8042-1775C14CC1D6Q35689824-0AE40435-50C8-42C7-BB45-4F30861BD350Q35903054-56AF1366-2345-43E5-8FE9-2827E278F422Q35951635-3457F72A-45B4-4B0F-B06A-9405CBEC519D
P2860
The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
The effects of induced hypogon ...... in males with prostate cancer.
@en
The effects of induced hypogon ...... in males with prostate cancer.
@nl
type
label
The effects of induced hypogon ...... in males with prostate cancer.
@en
The effects of induced hypogon ...... in males with prostate cancer.
@nl
prefLabel
The effects of induced hypogon ...... in males with prostate cancer.
@en
The effects of induced hypogon ...... in males with prostate cancer.
@nl
P2093
P356
P1476
The effects of induced hypogon ...... in males with prostate cancer.
@en
P2093
Cockcroft JR
Kynaston HG
Scanlon MF
P304
P356
10.1210/JC.86.9.4261
P407
P577
2001-09-01T00:00:00Z